ArticleBrain sciences2023
Pareto Optimized Adaptive Learning with Transposed Convolution for Image Fusion Alzheimer's Disease Classification.
Article in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 18 citations in OpenAlex.
- Hybrid Vision Transformer-CNN Framework for Alzheimer's Disease Cell Type Classification: A Comparative Study with Vision-Language Models.Journal of imaging · 2026Article
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Implications of Convolutional Neural Network for Brain MRI Image Classification to Identify Alzheimer's Disease.Parkinson's disease · 2024Article
- Optimized Convolutional Fusion for Multimodal Neuroimaging in Alzheimer's Disease Diagnosis: Enhancing Data Integration and Feature Extraction.Journal of personalized medicine · 2023Article
- Improving Alzheimer's Disease Classification in Brain MRI Images Using a Neural Network Model Enhanced with PCA and SWLDA.Healthcare (Basel, Switzerland) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurological condition that gradually weakens the brain and impairs cognition and memory. Multimodal imaging techniques have become increasingly important in the diagnosis of AD because they can help monitor disease progression over time by providing a more complete picture of the changes in the brain that occur over time in AD. Medical image fusion is crucial in that it combines data from various image modalities into a single, better-understood output. The present study explores the feasibility of employing Pareto optimized deep learning methodologies to integrate Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) images through the utilization of pre-existing models, namely the Visual Geometry Group (VGG) 11, VGG16, and VGG19 architectures. Morphological operations are carried out on MRI and PET images using Analyze 14.0 software and after which PET images are manipulated for the desired angle of alignment with MRI image using GNU Image Manipulation Program (GIMP). To enhance the network's performance, transposed convolution layer is incorporated into the previously extracted feature maps before image fusion. This process generates feature maps and fusion weights that facilitate the fusion process. This investigation concerns the assessment of the efficacy of three VGG models in capturing significant features from the MRI and PET data. The hyperparameters of the models are tuned using Pareto optimization. The models' performance is evaluated on the ADNI dataset utilizing the Structure Similarity Index Method (SSIM), Peak Signal-to-Noise Ratio (PSNR), Mean-Square Error (MSE), and Entropy (E). Experimental results show that VGG19 outperforms VGG16 and VGG11 with an average of 0.668, 0.802, and 0.664 SSIM for CN, AD, and MCI stages from ADNI (MRI modality) respectively. Likewise, an average of 0.669, 0.815, and 0.660 SSIM for CN, AD, and MCI stages from ADNI (PET modality) respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.